Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated infammatory conditions

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 3, 2009, Pages 329-336

  Walsh, Garry M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRFK 5; PLACEBO; RESLIZUMAB; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ASCARIASIS; ASTHMA; BONE PAIN; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILIC GASTROENTERITIS; EOSINOPHILIC POLYPOSIS; FATIGUE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPEREOSINOPHILIC SYNDROME; LOEFFLER PNEUMONIA; MULTIPLE CYCLE TREATMENT; NONHUMAN; NOSE POLYP; PROTEIN LOCALIZATION; PROVOCATION TEST; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EOSINOPHILS; HUMANS; INFLAMMATION; INTERLEUKIN-5; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 67650245693     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. 213355 Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. Egan RW, Athwahl D, Chou C-C, Emtage S, Jehn C-H, Kung TT, Mauser PJ, Murgolo NJ, Bodmer MW INT ARCH ALLERGY IMMUNOL 1995 107 1-3 321-322
2. 213357 Celltech Group plc. Celltech Group plc COMPANY BROCHURE 1996 March 20
3. 244726 Effects of an antibody to interleukin-5 in a monkey model of asthma. Mauser PJ, Pitman AM, Fernandez X, Foran SK, Adams GK III, Kreutner W, Egan RW, Chapman RW AM J RESPIR CRIT CARE MED 1995 152 2 467-472
4. 244727 Involvement of IL-5 in a murine model of allergic pulmonary infammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Kung TT, Stelts DM, Zurcher JA, Adams GKRD, Egan RW, Kreutner W, Watnick AS, Jones H, Chapman RW AM J RESPIR CELL MOL BIOL 1995 13 3 360-365
5. 244729 Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Mauser PJ, Pitman A, Witt A, Fernandez X, Zurcher J, Kung T, Jones H, Watnick AS, Egan RW, Kreutner W et al AM REV RESPIR DIS 1993 148 6 Pt 1 1623-1627
6. 290695 Structure and humanization of a rat monoclonal Fab to human interleukin-5. Cook WJ, Walter LJ, Murgolo NJ, Chou CC, Petro M, Zavodny PJ, Narula SK, Ramanathan L, Trotta PP, Nagabhushan TL PROTEIN ENG 1995 9 7 623-628
7. 290698 Interleukin 5 defciency abolishes eosinophilia, airway hyperreactivity, and lung damage in a mouse asthma model. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG J EXP MED 1996 183 1 195-201
8. 290701 Evaluation of airway hyperreactivity in interleukin-5 transgenic mice. Iwamoto T, Takatsu K INT ARCH ALLERGY IMMUNOL 1995 1 Suppl 1 28-30
9. 299419 Conquering airway infammation in the 21st century, National Heart & Lung Institute, London, UK. Norman P IDDB MEETING REPORT 1998 September 14-16
10. 331588 Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary infammation. Garlisi CG, Kung TT, Wang P, Minnicozzi M, Umland SP, Chapman RW, Stelts D, Crawley Y, Falcone A, Myers JG, Jones H AM J RESPIR CELL MOL BIOL 1999 20 2 248-255
11. 331593 Pulmonary biology of anti-interleukin 5 antibodies. Egan RW, Athwahl D, Chou CC, Chapman RW, Emtage S, Jenh CH, Kung TT, Mauser PJ, Murgolo NJ, Bodmer MW MEM INST OSWALDO CRUZ 1997 92 Suppl 2 69-73
12. 344295 Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Egan RW, Athwal D, Bodmer MW, Carter JM, Chapman RW, Chou CC, Cox MA, Emtage JS, Fernandez X, Genatt N, Indelicato SR et al ARZNEIMITTEL-FORSCH 1999 49 9 779-790
13. 467752 Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT et al LANCET 2000 356 9248 21444-21448
14. 474377 Drug development pipeline: Reslizumab. Celltech Group plc COMPANY COMMUNICATION 2002 December 18
15. 485205 Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Flood Page PT, Menzies Gow AN, Kay AB, Robinson DS AM J RESPIR CRIT CARE MED 2003 167 2 199-204
16. 494057 Technology evaluation: Mepolizumab, GlaxoSmithKline. Gnanakumaran G, Babu KS CURR OPIN MOL THER 2003 5 3 321-325
17. 552804 Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB J CLIN INVEST 2003 112 7 1029-1036
18. 758947 Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, Filipovich AH, Assa'ad AH, Rothenberg ME J ALLERGY CLIN IMMUNOL 2006 118 6 1312-1319
19. 778964 Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, Holtappels G, Tavernier J, van Cauwenberge P, Bachert C J ALLERGY CLIN IMMUNOL 2006 118 5 1133-1141
20. 839650 NCT00538434: Effcacy and safety study of reslizumab to treat eosinophilic esophagitis in subjects aged 5 to 18 years. Ception Therapeutics Inc CLINICALTRIALS.GOV 2007
21. 859033 Safety and effcacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB Blood 2004 103 8 2939-2941
22. 882863 Ception Therapeutics initiates phase II/III clinical trial for its lead product reslizumab in eosinophilic esophagitis (EE) in children. Ception Therapeutics Inc PRESS RELEASE 2008 March 05
23. 883272 Communication from Mike Beyer (Sam Brown Inc/Ception Therapeutics). Ception Therapeutics Inc COMPANY COMMUNICATION 2008 March 06
24. 885118 Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. Kim YJ, Prussin C, Martin B, Law MA, Haverty TP, Nutman TB, Klion AD J ALLERGY CLIN IMMUNOL 2004 114 6 1449-1455
25. 885120 Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, Danzig M, Cuss F, Pauwels RA AM J RESPIR CRIT CARE MED 2003 167 12 1655-1659
26. 885126 Pilot study of anti-IL-5 in eosinophilic gastroenteritis. Prussin C, James SP, Huber MM, Klion AD, Metcalfe DD J ALLERGY CLIN IMMUNOL 2003 111 2 Suppl S275
27. 887874 Treatment of patients with the hypereosinophilic syndrome with mepolizumab. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffn EF, Haig AE et al N Engl J Med 2008 358 12 1215-1228
28. 900222 Targeting TNF-α: A novel therapeutic approach for asthma. Brightling C, Berry M, Amrani Y J ALLERGY CLIN IMMUNOL 2008 121 1 5-10
29. 976250 Cephalon signs option agreement to buy Ception for $250 million. Cephalon Inc; Ception Therapeutics Inc PRESS RELEASE 2009 January 13
30. 979181 NCT00587288: Effcacy and safety of reslizumab to treat poorly controlled asthma. Ception Therapeutics Inc CLINICALTRIALS. GOV 2009
31. 982153 A study to evaluate safety and effcacy of mepolizumab in patients with moderate persistent asthma. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC AM J RESPIR CRIT CARE MED 2007 176 11 1062-1071
32. 989298 Advances in the immunobiology of eosinophils and their role in disease. Walsh GM CRIT REV CLIN LAB SCI 1999 36 5 453-496
33. 989329 Biology of interleukin-5 and its relevance to allergic disease. Egan RW, Umland SP, Cuss FM, Chapman RW ALLERGY 1996 51 2 71-81
34. 989345 Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousef S, Hein R, Smith T, Behrendt H, Ring J N Engl J Med 2003 349 24 2334-2339
35. 989353 The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Chusid MJ, Dale DC, West BC, Wolff SM MEDICINE 1975 54 1 1-27
36. 989365 Hypereosinophilic syndromes. Roufosse FE, Goldman M, Cogan E ORPHANET J RARE DIS 2007 2 37
37. 989370 Eosinophilic esophagitis: Management and pharmacotherapy. De Angelis P, Morino G, Pane A, Torroni F, Francalanci P, Sabbi T, Foschia F, Caldaro T, di Abriola GF, Dall'Oglio L EXPERT OPIN PHARMACOTHER 2008 9 5 731-740
38. 989374 Basic pathogenesis of eosinophilic esophagitis. Blanchard C, Rothenberg ME GASTROINTEST ENDOSC CLIN N AM 2008 18 1 133-143
39. 989380 Eotaxin-3 and a uniquely conserved gene-expression profle in eosinophilic esophagitis. Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, Jameson SC, Kirby C, Konikoff MR, Collins MH, Cohen MB et al J CLIN INVEST 2006 116 2 536-547
40. 989382 Decreased expression of membrane IL-5 receptor α on human eosinophils: I. Loss of membrane IL-5 receptor α on airway eosinophils and increased soluble IL-5 receptor α in the airway after allergen challenge. Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, Jarjour NN, Busse WW, Kelly EA J IMMUNOL 2002 169 11 6452-64528
41. 989384 Decreased expression of membrane IL-5 receptor α on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, Jarjour NN, Busse WW, Kelly EA J IMMUNOL 2002 169 11 6459-6466
42. 989389 Enhanced soluble interleukin-5 receptor α expression in nasal polyposis. Gevaert P, Bachert C, Holtappels G, Novo CP, Van der Heyden J, Fransen L, Depraetere S, Walter H, van Cauwenberge P, Tavernier J ALLERGY 2003 58 5 371-379
43. 989516 Anti-interleukin-5 treatment in nasal polyposis. Gevaert P, Van Zele T, Stammberger H, Sacks H, van Cauwenberge P, Bachert C J ALLERGY CLIN IMMUNOL 2005 115 2 Suppl Abs 553
44. 990459 Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM N Engl J Med 2009 360 10 985-993
45. 990468 Mepolizumab and exacerbations of refractory eosinophilic asthma. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID N Engl J Med 2009 360 10 973-984
46. 991608 Eosinophilic gastroenteritis: A review. Oh HE, Chetty R J GASTROENTEROL 2008 43 10 741-750
47. 991618 Pharmacologic treatment of eosinophilic esophagitis. Liacouras CA GASTROINTEST ENDOSC CLIN N AM 2008 18 1 169-178
48. 991623 Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Palframan RT, Collins PD, Williams TJ, Rankin SM Blood 1998 91 7 2240-2248
49. 991624 Chemokine and cytokine cooperativity: Eosinophil migration in the asthmatic response. Simson L, Foster PS IMMUNOL CELL BIOL 2000 78 4 415-422
50. 991625 Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. Collins PD, Marleau S, Griffths-Johnson DA, Jose PJ, Williams TJ J EXP MED 1995 182 4 1169-1174
51. 996498 TGF-β, eosinophils and IL-13 in allergic airway remodeling: A critical appraisal with therapeutic considerations. Fattouh R, Jordana M INFLAMM ALLERGY DRUG TARGETS 2008 7 4 224-236
52. 997999 Acute exacerbations of asthma: Epidemiology, biology and the exacerbation-prone phenotype. Dougherty RH, Fahy JV CLIN EXP ALLERGY 2009 39 2 193-202
53. 998001 Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis. Bullock JZ, Villanueva JM, Blanchard C, Filipovich AH, Putnam PE, Collins MH, Risma KA, Akers RM, Kirby CL, Buckmeier BK, Assa'ad AH et al J PEDIATR GASTROENTEROL NUTR 2007 45 1 22-31
54. 998002 Increased TGF-β2 in severe asthma with eosinophilia. Balzar S, Chu HW, Silkoff P, Cundall M, Trudeau JB, Strand M, Wenzel S J ALLERGY CLIN IMMUNOL 2005 115 1 110-1170